{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:27:49Z","timestamp":1790706469607,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T00:00:00Z","timestamp":1742688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12185-025-03970-w","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T11:53:10Z","timestamp":1742730790000},"page":"247-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early cardiotoxicity in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-haploidentical hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3778","authenticated-orcid":false,"given":"Toshihiro","family":"Matsukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,23]]},"reference":[{"issue":"6","key":"3970_CR1","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/jci124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Investig. 2019;129(6):2357\u201373. https:\/\/doi.org\/10.1172\/jci124218.","journal-title":"J Clin Investig"},{"issue":"1","key":"3970_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12185-019-02660-8","volume":"110","author":"J Sugita","year":"2019","unstructured":"Sugita J. HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol. 2019;110(1):30\u20138. https:\/\/doi.org\/10.1007\/s12185-019-02660-8.","journal-title":"Int J Hematol"},{"key":"3970_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101092","volume":"62","author":"M Mikulska","year":"2023","unstructured":"Mikulska M, Bartalucci C, Raiola AM, Oltolini C. Does PTCY increase the risk of infections? Blood Rev. 2023;62: 101092. https:\/\/doi.org\/10.1016\/j.blre.2023.101092.","journal-title":"Blood Rev"},{"issue":"5","key":"3970_CR4","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","volume":"68","author":"MA Goldberg","year":"1986","unstructured":"Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68(5):1114\u20138.","journal-title":"Blood"},{"issue":"6","key":"3970_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2008;14(6):641\u201350. https:\/\/doi.org\/10.1016\/j.bbmt.2008.03.005.","journal-title":"Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl"},{"issue":"3","key":"3970_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bjh.19228","volume":"204","author":"S Fuji","year":"2024","unstructured":"Fuji S, Sugita J, Najima Y, et al. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2024;204(3):959\u201366. https:\/\/doi.org\/10.1111\/bjh.19228.","journal-title":"Br J Haematol"},{"issue":"3","key":"3970_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","volume":"56","author":"J Sugita","year":"2021","unstructured":"Sugita J, Kamimura T, Ishikawa T, et al. Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation. Bone Marrow Transpl. 2021;56(3):596\u2013604. https:\/\/doi.org\/10.1038\/s41409-020-01065-0.","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"3970_CR8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41409-022-01770-y","volume":"57","author":"J Sugita","year":"2022","unstructured":"Sugita J, Atsuta Y, Nakamae H, et al. Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation. Bone Marrow Transpl. 2022;57(11):1681\u20138. https:\/\/doi.org\/10.1038\/s41409-022-01770-y.","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"3970_CR9","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004.","journal-title":"Blood"},{"issue":"12","key":"3970_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2009;15(12):1628\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004.","journal-title":"Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl"},{"issue":"36","key":"3970_CR11","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the european society of cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211.","journal-title":"Eur Heart J"},{"issue":"3","key":"3970_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/s0749-0704(05)70196-2","volume":"17","author":"C Shanholtz","year":"2001","unstructured":"Shanholtz C. Acute life-threatening toxicity of cancer treatment. Crit Care Clin. 2001;17(3):483\u2013502. https:\/\/doi.org\/10.1016\/s0749-0704(05)70196-2.","journal-title":"Crit Care Clin"},{"issue":"1","key":"3970_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s13104-017-2726-2","volume":"10","author":"K Kurauchi","year":"2017","unstructured":"Kurauchi K, Nishikawa T, Miyahara E, Okamoto Y, Kawano Y. Role of metabolites of cyclophosphamide in cardiotoxicity. BMC Res Notes. 2017;10(1):406. https:\/\/doi.org\/10.1186\/s13104-017-2726-2.","journal-title":"BMC Res Notes"},{"key":"3970_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114819","volume":"163","author":"YS Abulfadl","year":"2023","unstructured":"Abulfadl YS, El Ela YA, Al Khaiyat AM, Elkhodary KI, Badran M. Cyclophosphamide enfeebles myocardial isometric contraction force via RIP1\/RIP3\/MLKL\/TRPM7-mediated necroptosis. Biomed Pharmacother. 2023;163: 114819. https:\/\/doi.org\/10.1016\/j.biopha.2023.114819.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"3970_CR15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00277-016-2654-6","volume":"95","author":"S Ishida","year":"2016","unstructured":"Ishida S, Doki N, Shingai N, et al. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ann Hematol. 2016;95(7):1145\u201350. https:\/\/doi.org\/10.1007\/s00277-016-2654-6.","journal-title":"Ann Hematol"},{"issue":"10","key":"3970_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/sj.bmt.1704487","volume":"33","author":"M Sakata-Yanagimoto","year":"2004","unstructured":"Sakata-Yanagimoto M, Kanda Y, Nakagawa M, et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2004;33(10):1043\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1704487.","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"3970_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/sj.bmt.1705145","volume":"36","author":"K Oshima","year":"2005","unstructured":"Oshima K, Sakata-Yanagimoto M, Asano-Mori Y, et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant. 2005;36(9):821\u20134. https:\/\/doi.org\/10.1038\/sj.bmt.1705145.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3970_CR18","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/jco.1988.6.10.1562","volume":"6","author":"SI Bearman","year":"1988","unstructured":"Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol: Off J Am Soc Clin Oncol. 1988;6(10):1562\u20138. https:\/\/doi.org\/10.1200\/jco.1988.6.10.1562.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"24","key":"3970_CR19","doi-asserted-by":"publisher","first-page":"5599","DOI":"10.1182\/bloodadvances.2021004846","volume":"5","author":"J Yeh","year":"2021","unstructured":"Yeh J, Whited L, Saliba RM, et al. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021;5(24):5599\u2013607. https:\/\/doi.org\/10.1182\/bloodadvances.2021004846.","journal-title":"Blood Adv"},{"issue":"2","key":"3970_CR20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","volume":"3","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Mohty R, Labopin M, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC CardioOncol. 2021;3(2):250\u20139. https:\/\/doi.org\/10.1016\/j.jaccao.2021.02.011.","journal-title":"JACC CardioOncol"},{"issue":"10","key":"3970_CR21","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/bloodadvances.2022008792","volume":"7","author":"AI P\u00e9rez-Valencia","year":"2023","unstructured":"P\u00e9rez-Valencia AI, Cascos E, Carbonell-Ordeig S, et al. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant. Blood Adv. 2023;7(10):2018\u201331. https:\/\/doi.org\/10.1182\/bloodadvances.2022008792.","journal-title":"Blood Adv"},{"issue":"6","key":"3970_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11864-021-00850-3","volume":"22","author":"T L\u00f3pez-Fern\u00e1ndez","year":"2021","unstructured":"L\u00f3pez-Fern\u00e1ndez T, Vadillo IS, de la Gu\u00eda AL, Barbier KH. Cardiovascular issues in hematopoietic stem cell transplantation (HSCT). Curr Treat Options Oncol. 2021;22(6):51. https:\/\/doi.org\/10.1007\/s11864-021-00850-3.","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"3970_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/hon.3101","volume":"41","author":"R Yanagisawa","year":"2023","unstructured":"Yanagisawa R, Tamaki M, Tanoshima R, et al. Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese society for transplantation and cellular therapy transplant complications working group. Hematol Oncol. 2023;41(3):535\u201345. https:\/\/doi.org\/10.1002\/hon.3101.","journal-title":"Hematol Oncol"},{"issue":"4","key":"3970_CR24","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood-2003-07-2512","volume":"103","author":"KA Marr","year":"2004","unstructured":"Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103(4):1557\u20139. https:\/\/doi.org\/10.1182\/blood-2003-07-2512.","journal-title":"Blood"},{"issue":"5","key":"3970_CR25","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1111\/ajco.13674","volume":"18","author":"A Marumo","year":"2022","unstructured":"Marumo A, Omori I, Tara S, et al. Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg\/kg or less. Asia Pac J Clin Oncol. 2022;18(5):e507\u201314. https:\/\/doi.org\/10.1111\/ajco.13674.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"3970_CR26","doi-asserted-by":"publisher","first-page":"782.e1","DOI":"10.1016\/j.jtct.2021.06.011","volume":"27","author":"LJ Arcuri","year":"2021","unstructured":"Arcuri LJ, Hamerschlak N, Rocha V, Bonfim C, Kerbauy MN. Outcomes after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide: a systematic review and meta-analysis comparing myeloablative with reduced-intensity conditioning regimens and bone marrow with peripheral blood stem cell grafts. Transplant Cell Ther. 2021;27(9):782.e1-782.e7. https:\/\/doi.org\/10.1016\/j.jtct.2021.06.011.","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"3970_CR27","doi-asserted-by":"publisher","first-page":"928.e1","DOI":"10.1016\/j.jtct.2021.07.010","volume":"27","author":"T Tanaka","year":"2021","unstructured":"Tanaka T, Nakamae H, Ito A, et al. A Phase I\/II multicenter trial of HLA-Haploidentical PBSCT with PTCy for aggressive adult T cell leukemia\/lymphoma. Transplant Cell Ther. 2021;27(11):928.e1-928.e7. https:\/\/doi.org\/10.1016\/j.jtct.2021.07.010.","journal-title":"Transplant Cell Ther"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03970-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03970-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03970-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:12:36Z","timestamp":1757146356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03970-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3970"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03970-w","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,23]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JS is currently serving as an editor of International Journal of Hematology. However, the editorial process for the current manuscript was independently handled by other editorial board members, and he did not influence the review process or editorial decision. TT is an adviser or consultant for Astellas, Kyowa Kirin, Novartis, and Bristol Myers Squibb; reports research support from Astellas, Luca-science, Otsuka, Priothera SAS, Pharma Essentia Japan, AbbVie, IQVIA Japan, Chugai, Kyowa Kirin, CMIC, Novartis, Bristol Myers Squibb, Janssen, and CSL Behring; reports grants from Asahi-Kasei, Eisai, Kyowa Kirin, Shionogi, Sumitomo-Pharma, Chugai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}